Invitation: Isofol will present it’s contemplated IPO in Stockholm on March 29
In connection with the contemplated IPO of Isofol Medical on Nasdaq First North Premier, we are pleased to invite you […]
IR
Invitation: Isofol will present it’s contemplated IPO in Göteborg on March 22
In connection with the contemplated IPO of Isofol Medical on Nasdaq First North Premier, we are pleased to invite you
Listing of Isofol Medical on Nasdaq First North Premier and publication of prospectus
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA,
Isofol announces its intention to list on Nasdaq First North Premier
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA,
ISOFOL FILES IMPORTANT NEW US PATENT APPLICATION
Isofol Medical AB (publ) today announces that a new patent application was filed, on February 14, 2017, to the US
FDA CLEARS ISOFOL’S IND APPLICATION TO START CLINICAL PROGRAM WITHIN COLORECTAL CANCER WITH MODUFOLIN®
Isofol Medical AB announces that the US Food and Drug Administration (FDA) has cleared Isofol’s investigational new drug (IND) application
ISOFOL MEDICAL PRESENT AT AKTIETORGET INVESTOR MEETING
Isofol Medical AB presented at the AktieTorget investor meeting on Wednesday, October 5. This was a meeting arranged by SvD
ISOFOL MEDICAL HAS SUCCESSFULLY ADVANCED TO THE NEXT DOSE LEVEL OF MODUFOLIN® IN A PHASE I/II CLINICAL TRIAL IN COLORECTAL CANCER.
Isofol Medical AB today announced initiation of the next dose level of Modufolin®, in combination with 5-FU and oxaliplatin or
ISOFOL MEDICAL SHARE ISSUE OVERSUBSCRIBED, SECURING OVER SEK 39 MILLION TO STRENGTHEN THE ONGOING PHASE II CLINICAL DEVELOPMENT PROGRAM OF MODUFOLIN®
Isofol Medical AB, a clinical stage pharmaceutical company, developing novel products for unmet needs within oncology, will use the investment